We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Caffeine on Methacholine Challenge and Exhaled Nitric Oxide Levels.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01057875
First Posted: January 27, 2010
Last Update Posted: October 7, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of Saskatchewan
January 26, 2010
January 27, 2010
October 7, 2010
January 2010
February 2010   (Final data collection date for primary outcome measure)
methacholine pc20 [ Time Frame: 1 hour post ingestion ]
Same as current
Complete list of historical versions of study NCT01057875 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Caffeine on Methacholine Challenge and Exhaled Nitric Oxide Levels.
The Effects of Caffeine on Exhaled Nitric Oxide Levels and Methacholine PC20
To investigate whether or not the ingestion of caffeine with alter airway responsiveness to methacholine and/or change the level of exhaled nitric oxide.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Asthma
  • Other: caffeine
    Starbuck's Grande Pike Roast coffee
  • Other: No caffeine
    Starbuck's Grande Pike Roast Decaffeinated Coffee
  • Experimental: coffee with caffeine
    Intervention: Other: caffeine
  • Placebo Comparator: decaffeinated coffee
    Starbuck's Grande Pike Roast Decaf
    Intervention: Other: No caffeine
Yurach MT, Davis BE, Cockcroft DW. The effect of caffeinated coffee on airway response to methacholine and exhaled nitric oxide. Respir Med. 2011 Nov;105(11):1606-10. doi: 10.1016/j.rmed.2011.06.006. Epub 2011 Jul 2.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
February 2010
February 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • clinical diagnosis of asthma
  • FEV1 greater than 65%

Exclusion Criteria:

  • asthma is poorly controlled
  • presence of other airway disease (e.g. COPD)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01057875
BIO REB 09-186
No
Not Provided
Not Provided
Donald Cockcroft, MD, University of Saskatchewan
University of Saskatchewan
Not Provided
Principal Investigator: Donald W Cockcroft, MD University of Saskatchewan
University of Saskatchewan
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP